MSI-H/ MMRd

我们是谁

  • 10 月 31, 2023
    表达高亲和性 KRASG12V 突变特异性 T 细胞受体的自体 CD8+ 和 CD4+ 转基因 T 细胞（FH-A11KRASG12V-TCR）用于治疗 KRAS G12V 突变的转移性胰腺癌、结直肠癌和非小细胞肺癌患者
  • 10 月 17, 2023
    Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
  • 8 月 31, 2023
    A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
  • 8 月 31, 2023
    Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
  • 7 月 24, 2023
    Fc-Engineered Anti-CTLA-4 Monoclonal Antibody Botensilimab in Advanced Cancer
  • 4 月 12, 2023
    Evaluation for NCI Surgery Branch Immunotherapy Clinical Research Protocols
  • 4 月 12, 2023
    Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
  • 12 月 8, 2022
    Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
  • 12 月 8, 2022
    Evaluating Novel Therapies in ctDNA Positive GI Cancers
  • 12 月 8, 2022
    Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer